* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download Research and Development of Olopatadine hydrochloride, an
Polysubstance dependence wikipedia , lookup
Discovery and development of non-nucleoside reverse-transcriptase inhibitors wikipedia , lookup
Discovery and development of beta-blockers wikipedia , lookup
Discovery and development of angiotensin receptor blockers wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Cannabinoid receptor antagonist wikipedia , lookup
Pharmacokinetics wikipedia , lookup
Discovery and development of cephalosporins wikipedia , lookup
CCR5 receptor antagonist wikipedia , lookup
Toxicodynamics wikipedia , lookup
Drug design wikipedia , lookup
Discovery and development of ACE inhibitors wikipedia , lookup
Prescription costs wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Psychopharmacology wikipedia , lookup
NK1 receptor antagonist wikipedia , lookup
Tablet (pharmacy) wikipedia , lookup
Drug interaction wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Dydrogesterone wikipedia , lookup
Neuropharmacology wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Research and Development of Olopatadine hydrochloride, an Antiallergic Drug ○Etsuo Ohshima, Kenji Ohmori, and Hiroyuki Obase (Kyowa Hakko Kogyo Co., Ltd.) In terms of chemical structure, olopatadine would be distinguished from the other antiallergic drugs marketed so far. The compound possesses a dimethylamine moiety at the terminal of the side chain and a directly substituted acetic acid moiety on its tricyclic core structure. The introduction of a polar functional group to the tricyclic core was first attempted to reduce lipophilicity of an in-house lead compound in order to eliminate its CNS-related effects. Fortunately, the structural modifications provided a series of orally active compounds that showed retained antiallergic and reduced CNS-related effects in animal models. Further modifications were performed based both on the physicochemical properties and on the pharmacological activities. We finally selected olopatadine hydrochloride as a new drug candidate. Olopatadine has a potent and selective histamine H1 receptor antagonizing effect. Its physicochemical properties, including the water solubility of 2.0 mg/mL at pH6.8, eventually turned out to be suitable for ophthalmologic application as well. Two types of formulations containing olopatadine hydrochloride as the active ingredient, tablet and ophthalmic solution, were launched in 2001 (Japan) and in 1997 (USA), respectively. These prescriptions have contributed to the treatment of allergic disease conditions in 84 countries in the world up to now. The total annual sales of the R ) and the ophthalmic solution (Patanol○ R ) reached US$500 million in tablet (Allelock○ 2006 fiscal year. In this lecture, results of medicinal chemistry to provide olopatadine hydrochloride, properties of the compound, and some additional findings obtained from the research and development will be presented.